Medicare Coverage expands for NeoGenomics' PanTracer LBx blood test
The PanTracer LBx test by NeoGenomics has received CMS coverage under LCD - MolDX: L38043, enabling Medicare patients to access comprehensive blood-based genomic profiling for solid tumors, supporting personalized therapy and clinical trial options.
The PanTracer LBx test has received coverage from the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostics Services Program (MolDX) under LCD - MolDX: Plasma-Based Genomic Profiling in Solid Tumors (L38043), according to NeoGenomics.
Medicare patients can now receive coverage for the blood-based comprehensive genomic profiling (CGP) test, designed to support therapy selection and clinical trial enrollment in patients with advanced solid tumors.
The test evaluates more than 500 genes, providing actionable biomarker information from a simple blood draw within seven days. It can be ordered as a standalone test, as a reflex when tissue testing is insufficient, or concurrently with tissue analysis, providing flexibility to meet the needs of both patients and clinicians.
PanTracer LBx complements PanTracer Tissue to enable comprehensive pan-solid tumor profiling across care settings. Medicare patients can now access this noninvasive genomic test, expanding availability and reducing barriers to advanced cancer diagnostics.
